This video shows a case in our series of Descemet’s membrane endothelial keratoplasty in challenging cases, soon due for publication. The patient was referred to our clinic because of extensive corneal edema, due to multiple surgeries, following complicated cataract surgery. In addition to large peripheral anterior synechia (PAS) and aphakia, multiple vitrectomies were performed due to retinal detachments.
Alimera Sciences B.V., a subsidiary of Alimera Sciences, has signed an agreement with MEAgate International FZLLC to distribute Iluvien to treat diabetic macular edema in several Middle Eastern countries.According to the terms of the agreement, MEAgate…
An automated system for the detection of glaucoma may have a comparable performance for classification as compared with color fundus images viewed by trained ophthalmologists, according to a study.Because undiagnosed glaucoma is a large contributor to …
Dry eye is a multifactorial progressive disease that worsens with time. At the European Society of Cataract and Refractive Surgeons meeting in Barcelona, Ocular Surgery News convened anterior segment surgeons from both sides of the Atlantic to address …
Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a joint society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology.Genetic testing has long been a controversial t…
The impact of a Pfizer-Allergan merger on the world of U.S. eye care is a matter of speculation.Announced in November 2015, the agreement by the boards of directors of both companies allows for the smaller Ireland-based Allergan to acquire the larger U.S.-based Pfizer, putting Pfizer squarely into the ophthalmic space where it otherwise has a waning presence. The agreement is valued at $160 billion. Allergan’s legacy-rich products, including Restasis (cyclosporine ophthalmic emulsion 0.05%) and Lumigan (bimatoprost ophthalmic solution 0.01%), would bolster Pfizer’s product line.